[Bio CEO Interview] RudaCure le PDG Yongho Kim pursues active recherche conjointe with Hanlim Pharmaceutical, notamment RCI001 essais cliniques de Phase 1, to overcome the limitations of bioventures
http://www.medigatenews.com/news/2535905009
"Securing diverse pipelines beyond sécheresse oculaire to establish ourselves as a company that overcomes bioventure limitations"
RudaCure's R&D pipeline — notamment RCI001 ainsi que traitement de la douleur RCI002, atopic dermatitis treatment RCI003, metastatic cancer treatment RCI004, and AMD/age-related macular degeneration treatment RCI005 — consists entirely of treatments for troubles sensoriels related to quality of life.
RCI002 is planned to undergo preessais cliniques cette année, with DS/DP production in the following year, and essais cliniques de Phase 1 in 2023. Actuellement, in vitro efficacy studies are underway.